Literature DB >> 11753827

Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy.

Juan Berenguer1, Juan González, Federico Pulido, Belén Padilla, José Luis Casado, Rafael Rubio, José Rarmón Arribas.   

Abstract

We performed a prospective study of discontinuation of secondary prophylaxis against cytomegalovirus (CMV) in 36 patients with acquired immunodeficiency syndrome and quiescent CMV retinitis after successful treatment with highly active antiretroviral therapy (HAART). No reactivation or progression of retinitis was observed in 35 patients with persistent response to HAART, findings that support the discontinuation of secondary prophylaxis against CMV retinitis in such patients.

Entities:  

Mesh：

Year:  2001        PMID： 11753827     DOI： 10.1086/338401

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  7 in total

1.  Evaluation of the United States public health service guidelines for discontinuation of anticytomegalovirus therapy after immune recovery in patients with cytomegalovirus retinitis.

Authors:  Janet T Holbrook; Ryan Colvin; Mark L van Natta; Jennifer E Thorne; Mark Bardsley; Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2011-07-13       Impact factor: 5.258

Review 2.  HIV: primary and secondary prophylaxis for opportunistic infections.

Authors:  Judith Aberg; William Powderly
Journal:  BMJ Clin Evid       Date:  2010-06-28

3.  Cytomegalovirus retinitis in the highly active anti-retroviral therapy era.

Authors:  Ifeoma N Ude; Steven Yeh; Jessica G Shantha
Journal:  Ann Eye Sci       Date:  2022-03

4.  Economic evaluation of treatment administration strategies of ganciclovir for cytomegalovirus retinitis in HIV/AIDS patients in Thailand: a simulation study.

Authors:  Kanlaya Teerawattananon; Saniorn Iewsakul; Chawewan Yenjitr; Somsanguan Ausayakhun; Watanee Yenjitr; Miranda Mugford; Yot Teerawattananon
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy.

Authors:  A Antinori; A Ammassari; C Torti; P Marconi; M Andreoni; G Angarano; S Bonora; A Castagna; R Cauda; M Clerici; A d'Arminio Monforte; A De Luca; G Di Perri; M Galli; E Girardi; A Gori; A Lazzarin; S Lo Caputo; F Mazzotta; F Montella; C Mussini; C F Perno; M Puoti; G Rizzardini; S Rusconi; V Vullo; G Carosi
Journal:  Infection       Date:  2009-05-28       Impact factor: 3.553

Review 6.  Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective.

Authors:  Anna Thorner; Eric Rosenberg
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral Therapy Era.

Authors:  Hansjakob Furrer
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.663
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.